STRO

#2802
Sutro Biopharma, Inc.
35.8000 USD
+6.58%
Сектор: Здравоохранение
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
35.6777
35.9500
Годовой диапазон
16.7400
36.0000
Дневное изменение
+6.58%
Месячное изменение
+46.54%
6-месячное изменение
+105.87%
Годовое изменение
+105.87%
Предыдущее закрытие
33.5900
Открыть
35.9500
Минимум
35.6777
High
35.9500
Объем
5
Открыть полный график

Financials

Обзор Отчетность Статистика
Квартал Год
  • Market Capitalization 593.1071 M
  • Employee 137
  • Founded 2003
  • CEO N/A
  • Website www.sutrobio.com
  • Headquarter California, United States
  • FIGI BBG000R4V3P3
  • Industry Биотехнологии
Общий доход
Чистая прибыль
Базовая прибыль на акцию
Общий долг
Свободный денежный поток
Денежные средства и эквиваленты
Коэффициент цена/прибыль
-0.51
Коэффициент цена/денежный поток
0.96

Sutro Biopharma Inc

Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009. Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers.

Новости